Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 8, 2023
Daily News
February 8, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
- Japan Cabinet OKs Bill to Create Pandemic Response Agency
February 8, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Takhzyro Adds Pediatric Indication in US: Takeda
February 8, 2023
- Daiichi Sankyo Espha’s Nexium Generic Hits Japan Market
February 8, 2023
- MHLW Panel OKs 79 More Health Damage Claims for COVID-19 Vaccines
February 8, 2023
- Japan Ethical Drug Sales Surge 5.8% in December: Crecon
February 8, 2023
- CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
- MHLW Council’s Efforts to Address Drug Lag Led to 371 Approvals to Date: Minister
February 8, 2023
- ASKA, Japan Biotech Strike R&D Deal to Create VHH Therapies in OB-GYN Field
February 8, 2023
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…